{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-24-000043","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.432724+00:00","generated_at":"2026-06-03T06:31:27.413290+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BeiGene provides additional 2023 financial data including regional gross margins and product R&D","bullets":["Total revenue $2.46B; China gross margin 68.0% (2022: 67.1%), ex-China 98.0% (98.3%).","R&D expense by product: zanubrutinib $158M, tislelizumab $84M, pamiparib $9M, ociperlimab $78M.","Total R&D expenses $1.78B in 2023 vs $1.64B in 2022; internal R&D $1.13B.","Key products produced 5.0M vials, sold 3.88M vials; inventory 2.67M vials as of Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-24-000043","json":"https://secwatch.observer/filing/0001651308-24-000043.json","markdown":"https://secwatch.observer/filing/0001651308-24-000043.md","text":"https://secwatch.observer/filing/0001651308-24-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000043/0001651308-24-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000043/bgne-20240426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:31:27.413290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}